The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection
Open accessAbstract
SARS-CoV-2 is a novel coronavirus that is the causative agent of coronavirus infectious disease 2019 (COVID-19). As of 17 April 2020, it has infected 2 114 269 people, resulting in 145 144 deaths. The timing, magnitude and longevity of humoral immunity is not yet understood for SARS-CoV-2. Nevertheless, understanding this is urgently required to inform the likely future dynamics of the pandemic, to guide strategies to allow relaxation of social distancing measures and to understand how to deploy limiting vaccine doses when they become available to achieve maximum impact. SARS-CoV-2 is the seventh human coronavirus to be described. Four human coronaviruses circulate seasonally and cause common colds. Two other coronaviruses, SARS and MERS, have crossed from animal sources into humans but have not become endemic. Here we review what is known about the human humoral immune response to epidemic SARS CoV and MERS CoV and to the seasonal, endemic coronaviruses. Then we summarize recent, mostly non-peer reviewed, studies into SARS-CoV-2 serology and reinfection in humans and non-human primates and summarize current pressing research needs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
To, K. K.-W., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C.-Y., Cai, J.-P., Chan, J. M.-C., Chik, T. S.-H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,066
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H., & Lipsitch, M. (2020) · Science · doi:10.1126/science.abb5793 · Cited by 2,611 · cited 3×
“Thus, reinfection of previously mild SARS- CoV-2 cases is a realistic possibility that should be considered in models of a second wave and the post- pandemic era [21].”
BackgroundInfluentialAntibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607 · cited 2×
“At 2 weeks postsymptom onset, antibody titres were statistically higher in critical compared to non- critical patients, possibly due to different rates to a maximal antibody response or reflecting similar disease severity observations from MERSCoV and SARS- CoV patients as described above [30].”
BackgroundSusceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2
Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., Liu, R., He, X., Shuai, L., Sun, Z., et al. (2020) · Science · doi:10.1126/science.abb7015 · Cited by 1,911
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614
Coronavirus avian infectious bronchitis virus
Cavanagh, D. (2007) · Veterinary Research · doi:10.1051/vetres:2006055 · Cited by 1,053
Thevarajan, I., Nguyen, T. H. O., Koutsakos, M., Druce, J., Caly, L., van de Sandt, C. E., Jia, X., Nicholson, S., Catton, M., Cowie, B., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0819-2 · Cited by 1,013
Infection and Rapid Transmission of SARS-CoV-2 in Ferrets
Kim, Y.-I., Kim, S.-G., Kim, S.-M., Kim, E.-H., Park, S.-J., Yu, K.-M., Chang, J.-H., Kim, E. J., Lee, S., Casel, M. A. B., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.03.023 · Cited by 882
Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., et al. (2020) · doi:10.1101/2020.03.30.20047365 · Cited by 754
Respiratory disease in rhesus macaques inoculated with SARS-CoV-2
Munster, V. J., Feldmann, F., Williamson, B. N., van Doremalen, N., Pérez-Pérez, L., Schulz, J., Meade-White, K., Okumura, A., Callison, J., Brumbaugh, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2324-7 · Cited by 720
The time course of the immune response to experimental coronavirus infection of man
Callow, K. A., Parry, H. F., Sergeant, M., & Tyrrell, D. A. J. (1990) · Epidemiology and Infection · doi:10.1017/s0950268800048019 · Cited by 598
Bryan, A., Pepper, G., Wener, M. H., Fink, S. L., Morishima, C., Chaudhary, A., Jerome, K. R., Mathias, P. C., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00941-20 · Cited by 527
Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset
Lou, B., Li, T.-D., Zheng, S.-F., Su, Y.-Y., Li, Z.-Y., Liu, W., Yu, F., Ge, S.-X., Zou, Q.-D., Yuan, Q., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00763-2020 · Cited by 472
Evaluation of SARS-CoV-2 serology assays reveals a range of test performance
Whitman, J. D., Hiatt, J., Mowery, C. T., Shy, B. R., Yu, R., Yamamoto, T. N., Rathore, U., Goldgof, G. M., Whitty, C., Woo, J. M., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0659-0 · Cited by 454
Duration of Antibody Responses after Severe Acute Respiratory Syndrome
Wu, L.-P., Wang, N.-C., Chang, Y.-H., Tian, X.-Y., Na, D.-Y., Zhang, L.-Y., Zheng, L., Lan, T., Wang, L.-F., & Liang, G.-D. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1310.070576 · Cited by 426 · cited 1×
“indicate antibody titre reduced by 33 % within 1 year, 46 % by 2 years and ~75 % by 3 years [8].”
BackgroundTransmission of MERS-Coronavirus in Household Contacts
Drosten, C., Meyer, B., Müller, M. A., Corman, V. M., Al-Masri, M., Hossain, R., Madani, H., Sieberg, A., Bosch, B. J., Lattwein, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405858 · Cited by 393
Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery
Cao, W.-C., Liu, W., Zhang, P.-H., Zhang, F., & Richardus, J. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070348 · Cited by 367
Evaluation of nine commercial SARS-CoV-2 immunoassays
Lassaunière, R., Frische, A., Harboe, Z. B., Nielsen, A. C. Y., Fomsgaard, A., Krogfelt, K. A., & Jørgensen, C. S. (2020) · medRxiv · doi:10.1101/2020.04.09.20056325 · Cited by 317
Liu, W., Fontanet, A., Zhang, P., Zhan, L., Xin, Z., Baril, L., Tang, F., Lv, H., & Cao, W. (2006) · The Journal of Infectious Diseases · doi:10.1086/500469 · Cited by 285
MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015
Choe, P. G., Perera, R. A. P. M., Park, W. B., Song, K.-H., Bang, J. H., Kim, E. S., Kim, H. B., Ko, L. W. R., Park, S. W., Kim, N.-J., et al. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2307.170310 · Cited by 227
Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus
Payne, D. C., Iblan, I., Rha, B., Alqasrawi, S., Haddadin, A., Al Nsour, M., Alsanouri, T., Ali, S. S., Harcourt, J., Miao, C., et al. (2016) · Emerging Infectious Diseases · doi:10.3201/eid2210.160706 · Cited by 201
MO, H., ZENG, G., REN, X., LI, H., KE, C., TAN, Y., CAI, C., LAI, K., CHEN, R., CHAN‐YEUNG, M., et al. (2006) · Respirology · doi:10.1111/j.1440-1843.2006.00783.x · Cited by 193
The dominance of human coronavirus OC43 and NL63 infections in infants
Dijkman, R., Jebbink, M. F., Gaunt, E., Rossen, J. W. A., Templeton, K. E., Kuijpers, T. W., & van der Hoek, L. (2012) · Journal of Clinical Virology · doi:10.1016/j.jcv.2011.11.011 · Cited by 190
Human Coronavirus NL63 and 229E Seroconversion in Children
Dijkman, R., Jebbink, M. F., El Idrissi, N. B., Pyrc, K., Müller, M. A., Kuijpers, T. W., Zaaijer, H. L., & van der Hoek, L. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00533-08 · Cited by 185
Reed, S. E. (1984) · Journal of Medical Virology · doi:10.1002/jmv.1890130208 · Cited by 147
Antibody Response and Disease Severity in Healthcare Worker MERS Survivors
Alshukairi, A. N., Khalid, I., Ahmed, W., Dada, A. M., Bayumi, D. T., Malic, L. S., Althawadi, S., Ignacio, K. H., Alsalmi, H., Al-Abdely, H. M., et al. (2016) · Emerging infectious diseases · doi:10.3201/eid2206.160010 · Cited by 141
Quinlan, B. D., Mou, H., Zhang, L., Guo, Y., He, W., Ojha, A., Parcells, M. S., Luo, G., Li, W., Zhong, G., et al. (2020) · doi:10.1101/2020.04.10.036418 · Cited by 140
Gorse, G. J., Donovan, M. M., & Patel, G. B. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25715 · Cited by 134
Human Coronavirus NL63 Molecular Epidemiology and Evolutionary Patterns in Rural Coastal Kenya
Kiyuka, P. K., Agoti, C. N., Munywoki, P. K., Njeru, R., Bett, A., Otieno, J. R., Otieno, G. P., Kamau, E., Clark, T. G., van der Hoek, L., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy098 · Cited by 127
Self-citationLong-Term Persistence of IgG Antibodies in SARS-CoV Infected Healthcare WorkersPreprint
Guo, X., Guo, Z., Duan, C., Chen, Z., Wang, G., Lu, Y., Li, M., & Lu, J. (2020) · medRxiv · doi:10.1101/2020.02.12.20021386 · Cited by 92
Circulation of genetically distinct contemporary human coronavirus OC43 strains
Vijgen, L., Keyaerts, E., Lemey, P., Moës, E., Li, S., Vandamme, A., & Ranst, M. A. V. (2005) · Virology · doi:10.1016/j.virol.2005.04.010 · Cited by 86
Okba, N. M. A., Raj, V. S., Widjaja, I., GeurtsvanKessel, C. H., de Bruin, E., Chandler, F. D., Park, W. B., Kim, N. J., Farag, E., Al-Hajri, M., et al. (2019) · Emerging infectious diseases · doi:10.3201/eid2510.190051 · Cited by 79
Genetic drift of human coronavirus OC43 spike gene during adaptive evolution
Ren, L., Zhang, Y., Li, J., Xiao, Y., Zhang, J., Wang, Y., Chen, L., Paranhos‐Baccalà, G., & Wang, J. (2015) · Scientific Reports · doi:10.1038/srep11451 · Cited by 76
Aldridge, R. W., Lewer, D., Beale, S., Johnson, A. M., Zambon, M. C. F. A., Hayward, A. C., Fragaszy, E., & Flu Watch Group (2020) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15812.2 · Cited by 71
Ambrosioni, J., Bridevaux, P., Wagner, G., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12525 · Cited by 64
Antibody testing will enhance the power and accuracy of COVID-19-prevention trials
Lipsitch, M., Kahn, R. J., & Mina, M. J. (2020) · Nature Medicine · doi:10.1038/s41591-020-0887-3 · Cited by 59
Liu, L., Xie, J., Jianpin, S., Han, Y., Zhang, C., Fan, H., Liu, Z., Qiu, Z., He, Y., & Li, T. (2011) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2011.560184 · Cited by 34
Cited by
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.-H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201181 · Cited by 572
Germinal Center and Extrafollicular B Cell Responses in Vaccination, Immunity, and Autoimmunity
Elsner, R. A., & Shlomchik, M. J. (2020) · Immunity · doi:10.1016/j.immuni.2020.11.006 · Cited by 526
Safiabadi Tali, S. H., LeBlanc, J. J., Sadiq, Z., Oyewunmi, O. D., Camargo, C., Nikpour, B., Armanfard, N., Sagan, S. M., & Jahanshahi-Anbuhi, S. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00228-20 · Cited by 405
Metadata
- Authors
- Kellam, P., & Barclay, W.
- Venue
- Journal of General Virology
- Publisher
- Microbiology Society
- Published
- 2020-08-01
- Volume
- 101
- Issue
- 8
- Pages
- 791-797
- ISSN
- 0022-1317 (ISSN-L)
- 1465-2099
- OpenAlex
- W3017017672
- Cited by
- 351
- References
- 39
- FWCI
- 9.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.